Lantern Pharma has received regulatory approval to expand its Phase 2 clinical trial (HarmonicTM) to evaluate the efficacy of LP-300 for non-small cell lung cancersmall cell lung cancer (NSCLC) in non-smokers in Japan and Taiwan.
Approximately one-third of lung cancer cases in East Asia occur in non-smokers, a proportion that has been rising steadily. The expansion of the trial to these regions will accelerate the collection of data needed for further evaluation and development of LP-300 as a treatment for lung adenocarcinoma in non-smokers.
LCINS, characterized by distinct genetic and epidemiological features, has limited treatment options. Lantern believes that LP-300’s unique mechanism of action may provide a potential solution for this growing patient population.
Dr. Yashushi Goto of the National Cancer Center of Japan, a leading expert in lung cancer, will lead the trial in Japan. He expressed optimism about LP-300’s potential for NSCLC patients in East Asia, where EGFR mutations are prevalent.
The Harmonic trial is designed to assess the effects of LP-300 in combination with standard-of-care chemotherapy on the survival and disease progression of non-smoking patients with advanced NSCLC. The expansion to Japan and Taiwan is expected to provide valuable insights and contribute to the development of effective therapies for this patient population.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
